Alimentary Health enters partnership with Norgine.
26th August 2011. Alimentary Health Limited (AH), the specialty biotechnology company, today announces that it has entered into a development partnership with Norgine, a leading European specialty pharmaceutical company with a strong portfolio of internal development projects, principally in the areas of gastroenterology, hepatology and supportive care.
Under the partnership, AH and Norgine will collaborate on the evaluation of certain AH proprietary probiotic technology for development as a medicinal product for the treatment or management of gastrointestinal (GI) conditions. On conclusion of the programme, Norgine will have an option to negotiate a licence to commercialise the technology. Under the terms of the agreement, AH will receive an upfront payment from Norgine and is entitled to additional payments upon the completion of certain development milestones.
Dr. Barry Kiely, CEO of Alimentary Health, commented “We are very pleased to be entering this partnership with Norgine, a recognised leader in the commercialisation of pharmaceutical products for gastrointestinal conditions. We believe that the full therapeutic potential of probiotic technology is yet to be tapped. This partnership is further validation of AH’s technology and recognition of our position at the forefront of research into probiotic technology.”
Commenting on the deal, Paul Pay, Norgine’s VP of Corporate and Business Development said “This research collaboration is of great interest to Norgine as it signals our first move into the growing field of probiotics and we look forward to a fruitful collaboration with Alimentary Health.”
About Alimentary Health Ltd (AH).
AH is a specialty biotechnology company which is focused on the discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments for gastro-intestinal disorders and other inflammatory conditions. AH have a number of research relationships with leading global healthcare companies and has successfully developed probiotics for two products launched by Procter & Gamble, Align ® and Prostora (TM) Max, both of which are for sale in the United States. AH is the foundation industry partner of the Alimentary Pharmabiotic Centre based at University College Cork, Ireland.
Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine’s net product sales were €258 million. The Company employs over 1,200 people.
Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of traveller’s diarrhoea and ORAMORPH® for the treatment of moderate to severe pain.
Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.
For more information visit www.norgine.com